FilingReader Intelligence
Bloomage Biotech reports 2024 results, outlines cash distribution plan
April 10, 2025 at 05:20 PM UTC•By FilingReader AI
** Bloomage Biotechnology Corporation (SSE:688363) reported its 2024 financial results, including a consolidated revenue of CNY5.37 billion, a decline of 11.61% year-over-year. Amidst the performance figures, the company's board approved a plan to distribute a cash dividend of CNY0.11 per share, totaling approximately CNY52.62 million, showcasing a commitment to shareholder value despite a challenging year.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
Supplementary Source Documents
Deloitte Touche Tohmatsu Certified Public Accountants (Special General Partnership)'s 2024 Audit Report on Bloomage Biotech Co., Ltd.April 10, 2025 at 12:41 PM UTC
Summary of Bloomage Bio's 2024 Annual ReportApril 10, 2025 at 12:41 PM UTC
Announcement of Bloomage Biotechnology on the Provision of Large Asset Impairment in 2024April 10, 2025 at 12:41 PM UTC
Announcement of Bloomage Bio's 2024 Annual Profit Distribution PlanApril 10, 2025 at 12:41 PM UTC
Announcement of Bloomage Biotechnology on the Completion of Fundraising Projects and Cancellation of the Special Account for Fundraising FundsApril 10, 2025 at 12:41 PM UTC
SSE:688363•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Bloomage Biotechnology Corporation publishes news
Free account required • Unsubscribe anytime